Menu

Professional Practice Guidelines

  A number of medical specialty societies and expert groups have issued guidelines on hereditary cancer testing.  Myriad has formed its assessment criteria based on the following medical society guidelines.  A healthcare specialist may use assessment criteria based on that specialist's medical society guidelines, or based on his/her own professional judgment, which may differ from Myriad's assessment guidelines. BRACAnalysis® Testing for Hereditary Breast and Ovarian Cancer (HBOC) NCCN - National Comprehensive Cancer Network (login required)  - American Congress of Obstetricians and Gynecologists  - American Society of Breast Surgeons (pdf) ASCO® - American Society of Clinical Oncology  - Society of Gynecologic Oncology USPSTF - U.S. Preventive Services Task Force There may be additional professional practice guidelines for HBOC testing than those listed above that a healthcare specialist may want to consider, including the following:  - Association of Community Cancer Centers AMA - American Medical Association NSGC - National Society of Genetic Counselors ONS - Oncology Nursing Society  - Society of Gynecologic Oncology Society of Surgical Oncology logo - Society of Surgical Oncology COLARIS® and COLARIS AP® Testing for Lynch syndrome and Polyposis syndromes  -Association of Community Cancer Centers AMA - American Medical Association ASCRS - American Society of Colon and Rectal Surgeons AGA - American Gastroenterological Association ASCO® - American Society of Clinical Oncology NCCN - National Comprehensive Cancer Network NSGC - National Society of Genetic Counselors ONS - Oncology Nursing Society Society of Surgical Oncology logo - Society of Surgical Oncology  

BRACAnalysis, COLARIS, COLARIS AP, MELARIS, Myriad myPath, myPlan, myRisk, TheraGuide, PREZEON, PANEXIA, and Prolaris are either trademarks or registered trademarks of Myriad Genetics, Inc. in the United States and other jurisdictions